Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients
Orders Drug Makers to Offer Most-Favored-Nation Prices to Americans
What it does
Agencies must push drug makers to sell medicines to U.S. patients at the most-favored-nation price and pursue further actions if manufacturers do not comply.
Real-world impact
- May force drug companies to lower U.S. prices to match other countries.
- Could enable direct purchase of medicines by American patients at lower prices.
- Triggers export, import, and antitrust reviews affecting manufacturers' operations.
Topics
Summary
This order directs federal officials to secure "most-favored-nation" prices so American patients pay the same low prices other developed countries get. The Department of Health and Human Services must set price targets within 30 days and can support direct-to-consumer purchasing; trade and commerce officials must act against foreign practices that keep U.S. costs high.
If manufacturers do not comply, agencies may pursue rulemaking, importation approvals, antitrust enforcement, export reviews, or even revoke drug approvals. The goal is lower prescription costs for American consumers.
Questions, answered
Ask questions about this executive order and its implications. Try:
- “What agencies are affected by this order?”
- “How does this order change existing policy?”
- “What are the practical implications of this order?”